No Prescription |
 |
 | ||
|
ARRENO Aggrenox |
|
| ||
No Prescription » Prescription Drugs 2 » ARRENO Aggrenox The combination of aspirin and extended-release dipyridamole is in a class of drugs called antiplatelet agents. It works by preventing excessive blood clotting. It is used to reduce the risk of stroke in patients who have had or are at risk of stroke.The combination of aspirin and extended-release dipyridamole comes as a capsule to take by mouth. It is usually taken twice a day one capsule in the morning and one in the evening. Aspirin and extended-release dipyridamole should be swallowed whole. Do not open crush break or chew the capsules.The combination of aspirin and extended-release dipyridamole decreases the risk of having a stroke but does not eliminate that risk. Continue to take aspirin and extended-release dipyridamole even if you feel well. Do not stop taking aspirin and extended-release dipyridamole without talking to your doctor. Buy ARRENO Aggrenox and other Prescription Drugs 2 products online at Medstore. Buy Online at Medstore - Click Here!
About ARRENO Aggrenox: Product Type: Prescription Drugs 2 ARRENO ( Aggrenox Generic Aspirin/Dipyridamole ) ARRENO (Aggrenox Generic Aspirin/Dipyridamole) Aggrenox Generic Aspirin/Dipyridamole 25/200mg 3 x 60 Capsules-ER 60 Capsule-ER 2 x 60 Capsules-ER Aggrenox Generic Aspirin/Dipyridamole ARRENO
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
